Health Industry Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.

Press releases published on October 5, 2026

Oct. 5, 2026

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Indeterminate GlobeNewswire

Oct. 5, 2026

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Indeterminate GlobeNewswire

Oct. 5, 2026

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

Indeterminate GlobeNewswire

Oct. 5, 2026

Vireo Growth Inc. Announces Financing for New York and Florida Cultivation Facility

Indeterminate GlobeNewswire

Oct. 5, 2026

FIERCE BIOTECH NAMES REPRONOVO A “FIERCE 15” BIOTECH COMPANY OF 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

Kraig Biocraft Laboratories Ramps Full Production Across All Three Production Centers as Commercial Deliveries Begin to Take Hold

Indeterminate GlobeNewswire

Oct. 5, 2026

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

Indeterminate GlobeNewswire

Oct. 5, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 

Indeterminate GlobeNewswire

Oct. 5, 2026

Coave Therapeutics Presents Non-Human Primate Data Supporting Lead Wet AMD Gene Therapy Program at Euretina 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Indeterminate GlobeNewswire

Oct. 5, 2026

Satellos Granted Composition of Matter Patent for Forazapadin

Indeterminate GlobeNewswire

Oct. 5, 2026

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Indeterminate GlobeNewswire

Oct. 5, 2026

Iridex Completes Relocation of Manufacturing Facility to San Jose, California

Indeterminate GlobeNewswire

Oct. 5, 2026

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Indeterminate GlobeNewswire

Oct. 5, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

Indeterminate GlobeNewswire

Oct. 5, 2026

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Indeterminate GlobeNewswire

Oct. 5, 2026

Harrow Closes Acquisition of TYRVAYA®

Indeterminate GlobeNewswire

Oct. 5, 2026

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Indeterminate GlobeNewswire

Oct. 5, 2026

New Pico Laser for Tattoo Removal Includes Installation, On-Site Training and a Two-Year Warranty That Covers Technician Travel

Indeterminate GlobeNewswire

Oct. 5, 2026

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Indeterminate GlobeNewswire